Baxter recalls saline IV bags over fiberglass particles in a Class I action

Baxter Healthcare is recalling a large lot of one of the most routine products in any hospital: plain saline for intravenous use. The Food and Drug Administration recorded the action in its enforcement database on 9 September 2026, classifying it as Class I — the agency's most serious recall category, reserved for defects where use could cause serious injury or death [s1]. The reason stated in the record is blunt: the presence of particulate matter identified as fiberglass [s1].

What is affected

The recall covers 0.9% Sodium Chloride Injection USP in 500 mL Viaflex plastic containers, packed 24 units to a case, made in the United States and carrying national drug code 0338-0049-03 [s1]. Baxter's enforcement record lists 145,464 of the 500 mL bags in the affected quantity, distributed nationwide, from two lots, Y495523 and Y495523A, with an expiry date of 31 October 2027 [s1]. The company initiated the recall itself on 17 August 2026 and notified customers by letter, making this a voluntary, firm-initiated action rather than one ordered by the agency [s1]. As logged, the recall status is ongoing [s1].

Why saline particulates matter

Sodium chloride injection is about as basic as hospital pharmacy gets. Its label indications are simply a source of water and electrolytes, and, for the 0.9% strength, use as a priming solution in haemodialysis [s2]. It is infused directly into the bloodstream, often in volume and often in the sickest patients, which is exactly why a foreign-particle contaminant is treated so seriously.

Particulate matter injected intravenously bypasses the body's usual filters. Fiberglass fragments are rigid and do not dissolve, and the concern with any injectable particulate is that it can lodge in small vessels or provoke local reactions. The FDA's Class I designation reflects the potential severity of that hazard rather than a count of injuries; the enforcement record documents the defect and the scope of the recall, not patient outcomes [s1].

The exposure risk is also a function of how the product is used. Saline is frequently given in large volumes and as a carrier for other medicines, so a single contaminated bag can deliver its contents quickly and in quantity. The 500 mL Viaflex size named in the recall is a common ward and theatre presentation, and the two affected lots were shipped across the country rather than to a single region [s1].

The wider context

Saline bags are a supply-chain pressure point. They are high-volume, low-margin, and produced by a small number of manufacturers, so a single large recall can ripple into shortages at hospitals that keep limited stock. Baxter is one of the dominant suppliers of intravenous fluids in the United States, which is part of why a six-figure bag recall of a staple product draws notice well beyond the specific lots involved.

For clinicians and pharmacy teams, the immediate task set by a Class I recall is practical: identify whether any affected lots are on the shelves, quarantine them, and follow the manufacturer's instructions for return or replacement. Those operational steps sit with institutions, not patients, because saline of this kind is almost always administered in a clinical setting rather than at home.

How to read it

Two things are worth holding separate. The first is the hazard itself — a recognised, physical contaminant in a product that goes straight into the vein, which is why the agency applied its top classification [s1]. The second is that this is a defined, lot-specific recall of two lots with a known expiry, not a blanket withdrawal of Baxter saline [s1]. The enforcement record describes what was found and how much product is involved; it does not report that any patient was harmed, and the absence of such a report is not the same as proof that none occurred.

This article describes an FDA enforcement action and is not medical advice. Questions about intravenous fluids and any recall affecting a particular course of treatment are for the treating clinicians and the hospital pharmacy, who can check lot numbers against the agency's record.

Sources

• FDA Enforcement Report D-0849-2026: Baxter 0.9% Sodium Chloride Injection USP, 500 mL Viaflex — U.S. Food and Drug Administration, report date 9 September 2026
• Sodium Chloride Injection, USP (0.9%, Viaflex) — US prescribing information — U.S. Food and Drug Administration, label effective 24 July 2024